Brezivaptan

Brezivaptan
Clinical data
Other namesTS-121; TS121; TS-1211; TS1211; THY1773; THY-1773; ANC-501; ANC501
Routes of
administration		By mouth
Identifiers
  • 2-[3-(3-chlorophenyl)-1-[4-(2-morpholin-4-ylethyl)phenyl]-5-oxo-1,2,4-triazol-4-yl]-N-propan-2-ylacetamide
CAS Number
PubChem CID
UNII
ChEMBL
Chemical and physical data
FormulaC25H30ClN5O3
Molar mass484.00 g·mol−1
3D model (JSmol)
  • CC(C)NC(=O)CN1C(=NN(C1=O)C2=CC=C(C=C2)CCN3CCOCC3)C4=CC(=CC=C4)Cl
  • InChI=1S/C25H30ClN5O3/c1-18(2)27-23(32)17-30-24(20-4-3-5-21(26)16-20)28-31(25(30)33)22-8-6-19(7-9-22)10-11-29-12-14-34-15-13-29/h3-9,16,18H,10-15,17H2,1-2H3,(H,27,32)
  • Key:YCLGGNJZGIFVKX-UHFFFAOYSA-N

Brezivaptan[1] (developmental code names ANC-501, THY-1773, TS-121) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.[2][3][4] As of November 2022, it is in phase II clinical trials for this indication.[2][3][5]

See also

References

  1. ^ PubChem. "Brezivaptan". pubchem.ncbi.nlm.nih.gov. Retrieved 2024-08-15.
  2. ^ a b "TS 121 -". AdisInsight. Springer Nature Switzerland AG.
  3. ^ a b "New Drug Pipeline - Taisho Pharmaceutical Holdings".
  4. ^ Kamiya M, Sabia HD, Marella J, Fava M, Nemeroff CB, Umeuchi H, Iijima M, Chaki S, Nishino I (September 2020). "Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study". Journal of Psychiatric Research. 128: 43–51. doi:10.1016/j.jpsychires.2020.05.017. PMID 32521250. S2CID 219587135.
  5. ^ Inatani S, Mizuno-Yasuhira A, Kamiya M, Nishino I, Sabia HD, Endo H (May 2021). "Prediction of a clinically effective dose of THY1773, a novel V1B receptor antagonist, based on preclinical data". Biopharmaceutics & Drug Disposition. 42 (5): 204–217. doi:10.1002/bdd.2273. PMC 8252455. PMID 33734452.
  • Clinical trial number NCT03093025 for "A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder" at ClinicalTrials.gov



Stub icon

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.